Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Average Rating of “Moderate Buy” by Brokerages

Posted by Stanley Muller on Aug 23rd, 2026

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) has been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $38.50.

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Weiss Ratings raised shares of Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Lake Street Capital assumed coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 price target for the company. Finally, Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th.

View Our Latest Research Report on Aligos Therapeutics

Hedge Funds Weigh In On Aligos Therapeutics

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in shares of Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares in the last quarter. SummitTX Capital L.P. increased its stake in shares of Aligos Therapeutics by 6.7% in the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the period. Renaissance Technologies LLC increased its stake in shares of Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares during the period. Rockefeller Capital Management L.P. raised its holdings in Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Aligos Therapeutics in the 4th quarter valued at approximately $215,000. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Trading Up 3.6%

Shares of NASDAQ ALGS opened at $6.67 on Friday. The company has a market cap of $41.62 million, a price-to-earnings ratio of -0.91 and a beta of 2.31. Aligos Therapeutics has a 12 month low of $3.98 and a 12 month high of $13.69. The stock has a 50-day moving average price of $5.67 and a two-hundred day moving average price of $6.33.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.95. The company had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. On average, sell-side analysts predict that Aligos Therapeutics will post -6.81 earnings per share for the current year.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.